Bulletin
Investor Alert

New York Markets Open in:

UroGen Pharma Ltd.

NAS: URGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 13, 2020, 4:00 p.m.

/zigman2/quotes/202929873/composite

$

23.31

Change

0.00 0.00%

Volume

Volume 2,985

Quotes are delayed by 20 min

/zigman2/quotes/202929873/composite

Previous close

$ 23.35

$ 23.31

Change

-0.04 -0.17%

Day low

Day high

$23.21

$24.26

Open

52 week low

52 week high

$13.12

$37.08

Open

Annual Financials for UroGen Pharma Ltd.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue -17.53M8.16M1.13M18,000
Cost of Goods Sold (COGS) incl. D&A 113,000241,000600,0001.8M-
COGS excluding D&A -28,000393,0001.39M-
Depreciation & Amortization Expense 113,000213,000207,000417,0001.32M
Depreciation 113,000213,000207,000417,0001.32M
Amortization of Intangibles -----
Gross Income (113,000)17.29M7.56M(675,000)-
20152016201720182019 5-year trend
SG&A Expense 12.3M16.49M27.51M76.51M108.17M
Research & Development 10.52M10.29M18.7M36.93M49.3M
Other SG&A 1.78M6.2M8.81M39.57M58.88M
Other Operating Expense -----
Unusual Expense -----
EBIT after Unusual Expense -----
Non Operating Income/Expense (279,000)(2.74M)(31,000)(224,000)-
Non-Operating Interest Income ---1.87M4.62M
Equity in Affiliates (Pretax) -----
Interest Expense ----284,000
Gross Interest Expense ----284,000
Interest Capitalized -----
Pretax Income (12.69M)(1.94M)(19.98M)(75.53M)(105.15M)
Income Tax --19,000125,000-
Income Tax - Current Domestic --19,000125,000-
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (12.69M)(1.94M)(20M)(75.66M)(105.15M)
Minority Interest Expense -----
Net Income (12.69M)(1.94M)(20M)(75.66M)(105.15M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (12.69M)(1.94M)(20M)(75.66M)(105.15M)
Preferred Dividends 852,0002.47M825,000--
Net Income Available to Common (13.54M)(4.41M)(20.83M)(75.66M)(105.15M)
EPS (Basic) (1.13)(0.37)(2.14)(4.80)(5.12)
Basic Shares Outstanding 11.97M11.97M9.72M15.75M20.53M
EPS (Diluted) (1.13)(0.37)(2.14)(4.80)(5.12)
Diluted Shares Outstanding 11.97M11.97M9.72M15.75M20.53M
EBITDA (12.3M)1.01M(19.74M)(76.76M)(108.15M)
Link to MarketWatch's Slice.